Monthly information on share capital and company voting rights
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Cellectis (CLLS) has released its monthly share capital and voting rights report as of May 31, 2025. The company reported a total of 100,325,229 shares in its capital structure, with 89,110,384 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority. The company maintains its listing on Euronext Growth under the ISIN code FR0010425595.
Cellectis (CLLS) ha pubblicato il rapporto mensile sul capitale sociale e i diritti di voto aggiornato al 31 maggio 2025. La società ha comunicato un totale di 100.325.229 azioni nella sua struttura del capitale, con 89.110.384 diritti di voto complessivi. Questa comunicazione è effettuata in conformità all'Articolo 223-16 del Regolamento Generale dell'autorità francese dei mercati finanziari. L'azienda mantiene la sua quotazione su Euronext Growth con il codice ISIN FR0010425595.
Cellectis (CLLS) ha publicado su informe mensual sobre el capital social y los derechos de voto al 31 de mayo de 2025. La compañía reportó un total de 100.325.229 acciones en su estructura de capital, con 89.110.384 derechos de voto en total. Esta divulgación se realiza conforme al Artículo 223-16 del Reglamento General de la autoridad francesa de mercados financieros. La empresa mantiene su cotización en Euronext Growth bajo el código ISIN FR0010425595.
Cellectis(CLLS)는 2025년 5월 31일 기준 월간 자본금 및 의결권 보고서를 발표했습니다. 회사는 자본 구조에 총 100,325,229주의 주식을 보유하고 있으며, 총 의결권 수는 89,110,384입니다. 이 공시는 프랑스 금융시장청 일반규정 제223-16조에 따라 이루어졌습니다. 회사는 ISIN 코드 FR0010425595로 Euronext Growth에 상장되어 있습니다.
Cellectis (CLLS) a publié son rapport mensuel sur le capital social et les droits de vote au 31 mai 2025. La société a déclaré un total de 100 325 229 actions dans sa structure capitalistique, avec 89 110 384 droits de vote au total. Cette divulgation est effectuée conformément à l'article 223-16 du Règlement Général de l'Autorité des marchés financiers française. La société conserve sa cotation sur Euronext Growth sous le code ISIN FR0010425595.
Cellectis (CLLS) hat seinen monatlichen Bericht über das Grundkapital und die Stimmrechte zum 31. Mai 2025 veröffentlicht. Das Unternehmen meldete insgesamt 100.325.229 Aktien in seiner Kapitalstruktur sowie 89.110.384 Stimmrechte. Diese Offenlegung erfolgt gemäß Artikel 223-16 der Allgemeinen Verordnung der französischen Finanzmarktaufsicht. Das Unternehmen bleibt an Euronext Growth unter der ISIN FR0010425595 notiert.
Positive
- None.
Negative
- None.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, June 05, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 05/31/2025 | 100,325,229 | 89,110,384 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
What is the current total number of shares in Cellectis (CLLS) as of May 2025?
As of May 31, 2025, Cellectis has 100,325,229 total shares in its capital structure.
How many voting rights does Cellectis (CLLS) have as of May 2025?
Cellectis reported 89,110,384 total voting rights as of May 31, 2025.
Where is Cellectis (CLLS) stock listed?
Cellectis is listed on Euronext Growth under the ISIN code FR0010425595.
What is the difference between Cellectis total shares and voting rights in May 2025?
There is a difference of 11,214,845 between the total number of shares (100,325,229) and voting rights (89,110,384).
Cellectis